Harvoni scores another victory with inclusion on Prime’s preferred list

13 January 2015

US pharmacy Prime Therapeutics has agreed to provide hepatitis C drug Harvoni (ledipasvir/sofosbuvir) from US biotech major Gilead Sciences (Nasdaq: GILD) in a fresh victory for the company.

The announcement follows deals with US health insurance firms Anthem and CVS Health (NYSE: CVS) to provide the drug.

The agreement with Prime places both Gilead’s Harvoni and US drugmaker AbbVie’s (NYSE: ABBV) Viekira Pak (ombitasvir, paritaprevir and ritonavir tablets co-packaged with dasabuvir tablets) on its preferred drug list (formulary), meaning members can more easily get the medicine.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK